Drug Trial Radar · NCT07284979
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,270
Actual
Start
Dec 30, 2025
Primary completion
Mar 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- KaileraIndustry
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
Conditions
- Obesity
Interventions
RibupatideDrug
SC Injection
SemaglutideDrug
SC Injection
PlaceboDrug
SC Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Body Weight at Week 76Time frame: Baseline, Week 76
Locations
60 sites in 5 countries. Site status is shown where the registry gives one.
Kailera Clinical Site
Glendale, Arizona
Kailera Clinical Site
Phoenix, Arizona
Kailera Clinical Site
Little Rock, Arkansas
Kailera Clinical Site
Northridge, California
Kailera Clinical Site
Oceanside, California
Kailera Clinical Site
Hamden, Connecticut
Kailera Clinical Site
Stamford, Connecticut
Kailera Clinical Site
Orange City, Florida
Kailera Clinical Site
Albany, Georgia
Kailera Clinical Site
Chicago, Illinois
Kailera Clinical Site
Skokie, Illinois
Kailera Clinical Site
Newton, Kansas
Kailera Clinical Site
Shreveport, Louisiana
Kailera Clinical Site
Farmington Hills, Michigan
Kailera Clinical Site
Missoula, Montana
Kailera Clinical Site
Las Vegas, Nevada
Kailera Clinical Site
Albany, New York
Kailera Clinical Site
Morehead City, North Carolina
Kailera Clinical Site
Morrisville, North Carolina
Kailera Clinical Site
Norman, Oklahoma
Kailera Clinical Site
East Greenwich, Rhode Island
Kailera Clinical Site
North Charleston, South Carolina
Kailera Clinical Site
Spartanburg, South Carolina
Kailera Clinical Site
Brownsville, Texas
Kailera Clinical Site #1
San Antonio, Texas
Kailera Clinical Site #2
San Antonio, Texas
Kailera Clinical Site
Manassas, Virginia
Kailera Clinical Site
Richmond, Virginia
Kailera Clinical Site
Bruce, Australian Capital Territory, Australia
Kailera Clinical Site
Blacktown, New South Wales, Australia
Kailera Clinical Site
Kanwal, New South Wales, Australia
Kailera Clinical Site
Herston, Queensland, Australia
Kailera Clinical Site
Morayfield, Queensland, Australia
Kailera Clinical Site
South Brisbane, Queensland, Australia
Kailera Clinical Site
Camberwell, Victoria, Australia
Kailera Clinical Site
Montana, Bulgaria
Kailera Clinical Site
Sofia, Bulgaria
Kailera Clinical Site
Sofia, Bulgaria
Kailera Clinical Site
Stara Zagora, Bulgaria
Kailera Clinical Site
Pleven, Pleven Province, Bulgaria
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.